GENELUX Corp (GNLX) stock
Close on Nov 13, 2026Market cap $84.38MP/E –Yield –
GENELUX Corp grew revenue 0.0% to $8.00K over fiscal 2025. Free cash flow was -$28.68M. At the latest close the market valued the company at $84.38M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $84.38M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.24
- Dividend yield
- –
- Free cash flow yield
- -33.99%
Fundamentals
- Revenue
- $8.00K
- Net income
- -$35.60M
- EPS, diluted
- -$0.86
- Free cash flow
- -$28.68M
- Book value per share
- $0.36
- Diluted shares
- 45M
Trading
- Previous close
- $1.90
- Open
- $1.92
- Day's range
- $1.83 – $1.96
- Volume
- 179,403
- Average volume (20 days)
- 417,787
- Beta (5 years)
- 0.61
- 52-week range
- $1.77 – $6.01
- RSI (14 days)
- 38.8
- Volatility (1 year)
- 68.5%
- Relative volume
- 0.58×
- WACC
- 8.1%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | GNLX | S&P 500 | Difference | GNLX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.0% | -3.0% | −23.0 pts | ||
| 3 months | -29.1% | -2.8% | −26.3 pts | ||
| Year to date | -57.2% | +11.5% | −68.7 pts | ||
| 1 year | -66.2% | +13.5% | −79.6 pts | ||
| 3 years | -86.8% | +77.7% | −164.5 pts | -49.1% | +21.1% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Genelux filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- Update
- News
- Results
About Genelux
Pharmaceutical Preparations
Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies. The company designs off-the-shelf personalized treatments engineered to selectively destroy cancer cells and stimulate an immune response targeting unique tumor neoantigens. Its proprietary selection and development platform, CHOICE, leverages engineered strains of the vaccinia virus to establish an extensive library of product candidates. Its primary clinical candidate, Olvi-Vec, is evaluated across monotherapy and combination settings for patients with aggressive, difficult-to-treat solid tumors who have experienced limited success with conventional standards of care.
Company profile, executives and historyGenelux stock: common questions
What is Genelux's stock price?
GNLX closed at $1.86 on Nov 13, 2026, down 1.84% on the day. Over the past 52 weeks it traded between $1.77 and $6.01.
What is Genelux's market cap?
Genelux was worth $84.38M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is GNLX's P/E ratio?
Genelux lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.86), so it has no meaningful P/E ratio.
How much revenue does Genelux make?
Genelux reported revenue of $8.00K for fiscal 2025, up 0.0% from a year earlier.
Does Genelux pay a dividend?
No. Genelux has not paid a cash dividend over the last twelve months.
How has GNLX stock performed over the past year?
Including dividends, GNLX returned -66.2% over the past year, against +13.5% for the S&P 500.
How many GNLX shares are sold short?
5M shares were sold short at the latest FINRA report, 10.85% of the float, or 8.3 days of average trading volume.
Who are Genelux's competitors?
Companies most similar to Genelux by business, industry and size include LYEL, AZTR, CRVO, SYBX, CNBX.
See a number that looks wrong?